메뉴 건너뛰기




Volumn 34, Issue 10, 2007, Pages 2093-2098

Rasburicase for tophaceous gout not treatable with allopurinol: An exploratory study

Author keywords

Allergy; Allopurinol; Gout; Rasburicase; Renal failure; Treatment

Indexed keywords

ALLOPURINOL; COLCHICINE; CORTICOSTEROID; RASBURICASE; URIC ACID;

EID: 35148881765     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (89)

References (26)
  • 2
    • 33750374233 scopus 로고    scopus 로고
    • EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
    • Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-11.
    • (2006) Ann Rheum Dis , vol.65 , pp. 1301-1311
    • Zhang, W.1    Doherty, M.2    Pascual, E.3
  • 4
    • 18144366916 scopus 로고    scopus 로고
    • Recent advances in the management of gout and hyperuricemia
    • Wortmann RL. Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol 2005;17:319-24.
    • (2005) Curr Opin Rheumatol , vol.17 , pp. 319-324
    • Wortmann, R.L.1
  • 5
    • 33748608331 scopus 로고    scopus 로고
    • EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
    • Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
    • (2006) Ann Rheum Dis , vol.65 , pp. 1312-1324
    • Zhang, W.1    Doherty, M.2    Bardin, T.3
  • 6
    • 4043075471 scopus 로고    scopus 로고
    • Gout: On the brink of novel therapeutic options for an ancient disease
    • Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 2004;50:2400-14.
    • (2004) Arthritis Rheum , vol.50 , pp. 2400-2414
    • Bieber, J.D.1    Terkeltaub, R.A.2
  • 7
    • 20844447189 scopus 로고    scopus 로고
    • Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: Another insight to allopurinol-related toxicity
    • Perez-Ruiz F, Hernando I, Villar I, Nolla JM. Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight to allopurinol-related toxicity. J Clin Rheumatol 2005;11:129-33.
    • (2005) J Clin Rheumatol , vol.11 , pp. 129-133
    • Perez-Ruiz, F.1    Hernando, I.2    Villar, I.3    Nolla, J.M.4
  • 8
    • 33746717478 scopus 로고    scopus 로고
    • Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout
    • Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006;33:1646-50.
    • (2006) J Rheumatol , vol.33 , pp. 1646-1650
    • Dalbeth, N.1    Kumar, S.2    Stamp, L.3    Gow, P.4
  • 9
    • 10344228746 scopus 로고    scopus 로고
    • Current management of gout in patients unresponsive or allergic to allopurinol
    • Bardin T. Current management of gout in patients unresponsive or allergic to allopurinol. Joint Bone Spine 2004;71:481-5.
    • (2004) Joint Bone Spine , vol.71 , pp. 481-485
    • Bardin, T.1
  • 11
    • 0035147111 scopus 로고    scopus 로고
    • Efficacy and safety of desensitization to allopurinol following cutaneous reactions
    • Fam AG, Dunne SM, Iazzetta J, Paton TW. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum 2001;44:231-8.
    • (2001) Arthritis Rheum , vol.44 , pp. 231-238
    • Fam, A.G.1    Dunne, S.M.2    Iazzetta, J.3    Paton, T.W.4
  • 12
    • 0036240985 scopus 로고    scopus 로고
    • Rasburicase: A potent uricolytic agent
    • Pui CH. Rasburicase: a potent uricolytic agent. Exp Opin Pharmacother 2002;3:433-42.
    • (2002) Exp Opin Pharmacother , vol.3 , pp. 433-442
    • Pui, C.H.1
  • 13
    • 11844278229 scopus 로고    scopus 로고
    • Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy- associated hyperuricemia in pediatric and adult patients: Final results of a multicenter compassionate use trial
    • Jeha S, Kantarjian H, Irwin D, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy- associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005;19:34-8.
    • (2005) Leukemia , vol.19 , pp. 34-38
    • Jeha, S.1    Kantarjian, H.2    Irwin, D.3
  • 14
    • 14044273556 scopus 로고    scopus 로고
    • Urate oxidase (rasburicase) for treatment of severe tophaceous gout
    • Vogt B. Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol Dial Transplant 2005;20:431-3.
    • (2005) Nephrol Dial Transplant , vol.20 , pp. 431-433
    • Vogt, B.1
  • 15
    • 33746463120 scopus 로고    scopus 로고
    • Rasburicase treatment in severe tophaceous gout: A novel therapeutic option
    • Moolenburgh JD, Reinders MK, Jansen TL. Rasburicase treatment in severe tophaceous gout: a novel therapeutic option. Clin Rheumatol 2006;25:749-52.
    • (2006) Clin Rheumatol , vol.25 , pp. 749-752
    • Moolenburgh, J.D.1    Reinders, M.K.2    Jansen, T.L.3
  • 16
    • 33744963408 scopus 로고    scopus 로고
    • Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol
    • Richette P, Bardin T. Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol. Nat Clin Pract Rheumatol 2006;2:338-43.
    • (2006) Nat Clin Pract Rheumatol , vol.2 , pp. 338-343
    • Richette, P.1    Bardin, T.2
  • 18
    • 0034827359 scopus 로고    scopus 로고
    • Relation between adverse events associated with allopurinol and renal function in patients with gout
    • Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001;60:981-3.
    • (2001) Ann Rheum Dis , vol.60 , pp. 981-983
    • Vazquez-Mellado, J.1    Morales, E.M.2    Pacheco-Tena, C.3    Burgos-Vargas, R.4
  • 19
    • 0037352829 scopus 로고    scopus 로고
    • Elitek-rasburicase: An effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002
    • Navolanic PM, Pui CH, Larson RA, et al. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia 2003;17:499-514.
    • (2003) Leukemia , vol.17 , pp. 499-514
    • Navolanic, P.M.1    Pui, C.H.2    Larson, R.A.3
  • 20
    • 33645739675 scopus 로고    scopus 로고
    • Rasburicase: A review of its use in the management of anticancer therapy-induced hyperuricaemia
    • Oldfield V, Perry CM. Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia. Drugs 2006;66:529-45.
    • (2006) Drugs , vol.66 , pp. 529-545
    • Oldfield, V.1    Perry, C.M.2
  • 21
    • 33947232486 scopus 로고    scopus 로고
    • Rasburicase (Elitek): A novel agent for tumor lysis syndrome
    • Ueng S. Rasburicase (Elitek): a novel agent for tumor lysis syndrome. Proc Bayl Univ Med Cent 2005;18:275-9.
    • (2005) Proc Bayl Univ Med Cent , vol.18 , pp. 275-279
    • Ueng, S.1
  • 22
    • 0038102704 scopus 로고    scopus 로고
    • Rasburicase for the treatment and prevention of hyperuricemia
    • Yim BT, Sims-McCallum RP, Chong PH. Rasburicase for the treatment and prevention of hyperuricemia. Ann Pharmacother 2003;37:1047-54.
    • (2003) Ann Pharmacother , vol.37 , pp. 1047-1054
    • Yim, B.T.1    Sims-McCallum, R.P.2    Chong, P.H.3
  • 23
    • 27344455353 scopus 로고    scopus 로고
    • Hemolysis and methemoglobinemia secondary to rasburicase administration
    • Browning LA, Kruse JA. Hemolysis and methemoglobinemia secondary to rasburicase administration. Ann Pharmacother 2005;39:1932-5.
    • (2005) Ann Pharmacother , vol.39 , pp. 1932-1935
    • Browning, L.A.1    Kruse, J.A.2
  • 24
    • 14944345365 scopus 로고    scopus 로고
    • Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout
    • Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005;52:916-23.
    • (2005) Arthritis Rheum , vol.52 , pp. 916-923
    • Becker, M.A.1    Schumacher Jr, H.R.2    Wortmann, R.L.3
  • 25
    • 28944437578 scopus 로고    scopus 로고
    • Febuxostat compared with allopurinol in patients with hyperuricemia and gout
    • Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61.
    • (2005) N Engl J Med , vol.353 , pp. 2450-2461
    • Becker, M.A.1    Schumacher Jr, H.R.2    Wortmann, R.L.3
  • 26
    • 33947119693 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout
    • Sundy JS, Ganson NJ, Kelly SJ, et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 2007;56:1021-8.
    • (2007) Arthritis Rheum , vol.56 , pp. 1021-1028
    • Sundy, J.S.1    Ganson, N.J.2    Kelly, S.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.